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ABSTRACT 
 
PURPOSE 
The purpose of the eSMART (Electronic Symptom Management using the Advanced Symptom 
Management System (ASyMS) Remote Technology) study is to evaluate the use of mobile phone 
technology to manage chemotherapy-related toxicities (CRTs) in people with breast cancer (BC), 
colorectal cancer (CRC), Hodgkin’s lymphoma (HL), and non-Hodgkin lymphoma (NHL)) across 
multiple European sites. One key objective was to review the published and grey literature on 
assessment and management of CRTs among patients receiving primary chemotherapy for BC, CRC, 
HL, and NHL to ensure that ASyMS remained evidence-based and reflected current and local 
practice. 
 
METHODS: 
Three electronic databases were searched for English papers, with abstracts available from 
01/01/2004-05/04/2014. For the grey literature, relevant clinical practice guidelines 
(CPGs)/evidence-based resources (EBRs) from the main international cancer organisations were 
reviewed as were symptom management (SM) protocols from the sites. 
RESULTS: 
After full-text screening, 27 publications were included. The majority (n=14) addressed fatigue and 
focused on BC patients. Relevant CPGs/EBRs were found for fatigue (n=4), nausea/vomiting (n=5), 
mucositis (n=4), peripheral neuropathy (n=3), diarrhoea (n=2), constipation (n=2), febrile 
neutropenia/infection (n=7), palmar plantar erythrodysesthesia (PPE) (n=1), and pain (n=4). SM 
protocols were provided by >40% of the clinical sites. 
 
CONCLUSIONS: 
A need exists for empirical research on SM for PPE, diarrhoea, and constipation. Research is needed 
on the efficacy of self-care strategies in patients with BC, CRC, HL, and NHL. In general, consistency 
exists across CPGs/EBRs and local guidelines on the assessment and management of common CRTs.   
 
Keywords: assessment; management; chemotherapy; toxicity; symptom; scoping review; clinical 
practice guideline, self-care 
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The assessment and management of chemotherapy-related toxicities in 
patients with breast cancer, colorectal cancer, and Hodgkin and non-Hodgkin 
lymphomas: a scoping review 
Introduction 
 
In 2013, the European Union (EU) funded eSMART1; a study evaluating Electronic Symptom 
Management using the Advanced Symptom Management System (ASyMS2)  mobile phone 
technology for the management of chemotherapy-related toxicities (CRTs) in people with breast 
cancer (BC), colorectal cancer (CRC), Hodgkin’s lymphoma (HL), and non-Hodgkin lymphoma (NHL)) 
cancers across multiple clinical sites in Europe. Developed in conjunction with cancer clinicians and 
people with cancer (Kearney et al., 2006, Gibson et al., 2009, Kearney et al., 2009, Gibson et al., 
2010, Maguire et al., 2015), ASyMS is a mobile phone based remote monitoring system that enables 
real time monitoring of CRTs through patients’ completion of electronic patient reported outcome 
measures (ePROMs). ASyMS facilitates immediate tailored management of CRTs in the home care 
setting, automatic and immediate triaging of care when toxicities exceed clinical norms, and the 
provision of evidence-based self-care advice. 
At the outset, a key objective of eSMART was to undertake a review of the published and grey 
literature (international, national and local clinical guidelines) related to the assessment and 
management of CRTs among patients receiving primary chemotherapy for BC, CRC, NHL, and HL to 
ensure that ASyMS (risk algorithms, symptom protocols, self-care advice) was evidence-based, 
updated3, and reflected current and local practice. Consistent with the toxicities assessed and 
managed using ASyMS, this review was limited to the most common CRTs (i.e., nausea, vomiting, 
diarrhoea, constipation, mucositis/stomatitis, chemotherapy induced peripheral neuropathy (CIPN), 
hand-foot syndrome (palmar plantar erythrodysesthesia (PPE)), fever (or febrile neutropenia (FN)), 
infection, fatigue, pain). The purpose of this paper is to report on the background, objectives, 
methods, and key findings from the published and grey literature review.  
Methods 
Search Strategy (published literature) 
With the assistance of a college librarian, a search strategy with five search strings (Figure 1, 
Appendix 1) was designed. This search was conducted within three electronic databases (i.e., 
PubMed, CINAHL, PsycARTICLES) using specific Boolean operators, truncation markers, and MeSH 
headings. All searches were limited to English papers, involving human participants over 18 years of 
age, with an abstract available dating from January 1st 2004 to April 5th 2014. Given the recent 
literature review3, it was deemed sufficient to target empirical literature published within the 
previous ten years. The results were exported into WebEndNote© and articles were screened in two 
                                                          
1 Electronic Symptom Management using the Advanced Symptom Management System 
2 Advanced Symptom Management System 
3 The content of the existing system was rigorously developed following systematic reviews of the literature 
and expert clinician consensus in the UK and Australia in 2011. 
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stages. First, titles and abstracts of all retrieved articles were screened for eligibility by two 
reviewers (CP1, AD). Where relevance was unclear from the title or abstract, a copy of the full text 
was obtained. 
One hundred and eighty articles met the inclusion criteria (see Table 1) and full text versions were 
obtained. The second phase of screening involved assessment of the full texts (N=180) by five 
reviewers (CP1, AD, EF, PF, AM).  Studies were selected if they met the inclusion criteria. To further 
ensure the quality of the included literature, articles were required to meet the criteria outlined by 
the UK’s Department of Health (DoH) ‘Typology of Supportive Evidence’ (UK DoH, 2011) (Table 1). 
Once all of the articles were screened, the eligibility outcomes were cross-checked and examined by 
a sixth reviewer (CP2). This reviewer was given 10% of the full text articles to compare her rating of 
outcomes with those of the original screening team. Seven discrepancies were identified and three 
reviewers (CP1, CP2, AD) made the final decision regarding relevance. A PRISMA diagram of the 
systematic review process that depicts the reasons for inclusion and exclusion criteria of articles is 
presented in Figure 2.  
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Table 1 Eligibility guidelines for screening citations 
In the context of patients diagnosed with either BC, CRC, NHL, or HL, studies which 
 
Inclusion  
Criteria 
1. included adult patients (18+ years)  
2. focused exclusively on symptom management and self-care strategies for nausea, 
vomiting, diarrhoea, constipation, fever (or FN), infection, CIPN, mucositis (or 
stomatitis), fatigue, PPE, pain  
3. investigated self-care strategies (as a primary outcome)  
4. involved aspects of symptom management and/or assessment conducted by 
clinicians  
5. reviewed the use of complementary and alternative medicine (CAM) therapies that 
were relevant to self-care of the symptoms of interest 
Exclusion 
Criteria 
1. focused on the experience (or prevalence) of symptoms with no reference to 
management or self-care 
2. reported results of CAM therapies 
3. focused on patients with Burkitt’s lymphoma; patients < 18 years; patients in 
survivorship following chemotherapy completion; patients with metastatic disease 
and in the context of palliative care; patients undergoing bone marrow 
transplantation (BMT) 
4. reported validation of tools 
5. focused on symptoms not listed in the inclusion criteria 
6. investigated the use of medicinal products to treat or manage CRTs 
Typology of the level of evidence (adapted from UK Department of Health) 
Included 
Papers 
A1 Systematic reviews which included at least one randomised controlled trial (RCT) 
(e.g. Systematic Reviews from Cochrane or Centre for Reviews and Dissemination). 
A2 Other systematic and high quality reviews which synthesise references. 
B1 Individual RCTs. 
B2 Individual non-randomised, experimental/intervention studies. 
B3 Individual well-designed non-experimental studies, controlled statistically if 
appropriate; includes studies using case control, longitudinal, cohort, matched 
pairs, or cross-sectional random sample methodologies, and well-designed 
qualitative studies; well-designed analytical studies including secondary analysis. 
Excluded 
Papers 
C1 Descriptive and other research or evaluation not in B (e.g. convenience samples). 
C2 Case studies and examples of good practice. 
D Summary review articles and discussions of relevant literature and conference 
proceedings not otherwise classified. 
 
 5 
 
Once the final set of relevant papers were identified (N=27), key data were extracted and tabulated 
(see Appendix 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Screening process  
 
 
Methods adopted to review the grey literature  
 
This scoping review included a focused appraisal of the relevant grey literature to minimise the 
omission of important information which is not published (Blackhall and Ker, 2007). This approach 
included a review of symptom management protocols across the participating clinical sites (N=13) in 
the study to achieve consistency with reference to the symptom management and self-care advice 
utilised for ASyMS. More specifically, relevant clinical practice guidelines (CPGs)/evidence-based 
resources (EBRs) from the main international medical and nursing cancer organisations were 
reviewed (i.e., the European Society for Medical Oncology (ESMO), the American Society for Clinical 
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Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), the Multinational 
Association for Supportive Care in Cancer (MASCC), the Oncology Nursing Society (ONS), the 
European Oncology Nursing Society (EONS)). While acknowledging that some were published, 
CPGs/EBRs were included under the grey literature heading to decrease the likelihood of omitting 
guidelines that were not published in journals (e.g., EONS guidelines and ONS Putting Evidence into 
Practice (PEP) online resources). The United Kingdom Oncology Nursing Society (UKONS) was the 
only national organisation with symptom management guidelines available in English. In addition, 
each clinical site involved in the study was asked to provide copies of their symptom management 
protocols and/or guidelines if they were available in English. 
Results 
 
The findings from this review are structured around each of the symptoms, that is, each symptom is 
discussed with reference to the relevant published and grey literature. For the published literature, 
the initial search strategy elicited 7,268 unique publications. After a full-text screening process, 27 
publications were included in this review. The majority of the papers were either reviews (n=7, 
including four systematic reviews (SR)) or RCTs (n=7). With the exception of a single arm pilot study, 
the remaining studies were descriptive utilising a quantitative (n=9), qualitative (n=2), or mixed 
methods (n=1) approach (Appendix 2). The majority of the papers (n=14) addressed fatigue (either 
as a primary or secondary endpoint in intervention studies or in addition to other symptoms in the 
reviews and descriptive studies) and these papers primarily focused on patients with BC. Nine 
papers addressed multiple symptoms while CIPN was the focus of three papers. Chemotherapy-
induced nausea and vomiting (CINV) were addressed separately in two papers and together in one 
paper. Oral mucositis (OM) and pain were both the focus of two separate papers. None of the 
papers focused on symptom management for diarrhoea, constipation, or PPE. The majority of the 
studies addressed various interventions for symptom management. Only three papers (Chou et al., 
20074, Speck et al., 2012, Spichiger et al., 2012) addressed self-care strategies.  
Relevant CPGs/EBRs were found for fatigue (n=4), CINV (n=5), OM (n=4), CIPN (n=3), diarrhoea (n=2), 
constipation (n=2), FN/neutropenic sepsis/infection (n=7), PPE (n=1), and pain (n=4) (Appendix 3, 
Tables 4-12, inclusive). Information on symptom management protocols and self-care guidance was 
provided by over 40% of the participating clinical sites (sites did not have the protocols/guidance 
available in English and/or did not have institution-specific guidelines) (Tables 3-12, inclusive).  
Fatigue  
The review of the published literature found 14 papers on fatigue. Ten of these studies focused on 
various fatigue-related symptom management interventions. However, with the exception of one 
study that evaluated the effect of exercise on patients with lymphoma (Courneya et al., 2009), the 
others focused on fatigue in BC. None of the studies addressed symptom management interventions 
(other than self-care) for fatigue in CRC. More specifically, this review found two multicentre RCTs 
(Courneya et al., 2007a, Courneya et al., 2007b, Courneya et al., 2013) and one single arm pilot study 
(Ligibel et al., 2010) that focused on the impact of exercise for the management of fatigue in women 
receiving adjuvant treatment for BC . 
                                                          
4 According to Chou et al. (2007), approximately 2-3 self-care strategies were used to manage each symptom 
reported in their study. While the specific self-care strategies were not identified, they were reported to be of 
low to moderate effectiveness. 
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Although initially, neither aerobic exercise training (AET) nor resistance exercise training (RET) 
significantly improved fatigue levels over usual care, positive trends were noted for both exercise 
groups (Courneya et al., 2007a). Moreover, a six month post-intervention follow-up of the same 
study (Courneya et al., 2007b) reported improved levels of fatigue (p=.013) for patients who 
confirmed adherence to both AET and RET. Ligibel and colleagues (2010) reported a trend toward 
improved fatigue levels in a similar cohort of patients who completed a home-based, 12 week 
moderate-intensity aerobic exercise intervention with telephone counselling. More recently, 
Courneya et al. (2013) reported that a higher dose (50-60 minutes) of aerobic or combined exercise 
(aerobic and resistance) were both feasible and safe for patients receiving adjuvant chemotherapy 
for BC and may be superior to standard doses (25-30 minutes) for managing symptoms such as 
fatigue.  
The benefit of exercise for the management of fatigue both during and after treatment for BC was 
highlighted in three reviews (two SR (Kirshbaum, 2006, Wanchai et al., 2011) and one non-
systematic but comprehensive review (Loprinzi et al., 2008)). Wanchai and colleagues (2011) 
suggested that other interventions such as education and counselling, sleep therapy, and 
complementary therapy (CT) were likely to be beneficial for managing fatigue in BC. Courneya et al. 
(2009) evaluated the impact of 12 weeks of supervised AET versus usual care for patients with HL 
and NHL, receiving chemotherapy or no treatment. According to the authors, the AET group had 
superior effects for outcomes including fatigue (p=.013).   
Only one study (Spichiger et al., 2012) explicitly addressed self-care strategies used to decrease 
cancer-related fatigue. According to the authors, patients with lymphoma, BC, CRC, and lung cancer 
employed various intuitive self-care approaches (most often rest) to manage their fatigue although 
they had difficulty explaining their rationale for the approaches chosen or whether or not they were 
effective. In addition, Spichiger et al. (2012) found that while patients reported that they were well 
informed about fatigue by clinicians on commencing chemotherapy, virtually no fatigue 
management support was provided during chemotherapy. Chou et al. (2007) reported on self-care 
strategies used for chemotherapy-induced fatigue4.  
Four cancer organisations developed fatigue specific CPGs/EBRs, namely, UKONS (2013), ASCO 
(Bower et al., 2014), ONS (Mitchell et al., 2007, ONS, 2014), and the NCCN (2014) (Table 4).  The 
ASCO (2014) guideline was developed to address fatigue in adult cancer survivors following 
completion of primary therapy. Focused on patients who present as an emergency/unplanned 
admission, the UKONS (2013) guideline is more relevant for the initial rather than the long term 
management of fatigue. That said, all of the guidelines are broadly consistent with reference to 
fatigue assessment and management. In terms of assessment, the guidelines highlight the 
importance of regular screening for fatigue and the utilisation of assessment tools and 
comprehensive history taking to identify fatigue and treatable contributing factors. Similarly, the 
symptom management strategies recommended for fatigue are broadly consistent, including 
exercise, treatment of contributing factors, various psychoeducational interventions, cognitive 
behavioural therapy (CBT)/behavioural therapy (BT), CT and if necessary medications such as 
psychostimulants. 
Guidelines for fatigue assessment and management were only available from one clinical site and 
were for the purpose of telephone triage (Table 4).  Although more focused in nature, the 
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assessment and management of fatigue outlined in these guidelines was congruent with those of 
the international cancer organisations although they do not explicitly identify exercise as an 
intervention. A protocol followed by three clinical sites recommended that patients with BC who are 
experiencing fatigue should, where appropriate, receive a referral to rehabilitation specialists for 
guidance on rest and exercise. Of note, this protocol addressed the assessment and management of 
issues related to BC in general, rather than to fatigue specifically.  
CINV 
While acknowledging that they are separate phenomena (Grunberg, 2004), nausea and vomiting are 
discussed together within this context given the limited number of primary studies identified in the 
published literature for either toxicity. In total, six papers addressed either nausea or vomiting or 
both (primarily in BC). However, only two of these papers discussed symptom management 
interventions. In 2008, Lee et al. conducted a secondary analysis of data from a longitudinal, 
multicentre, RCT that examined the effectiveness of a systematic exercise intervention during and 
after adjuvant BC treatment. According to the authors, patients who exercised had significantly less 
intense nausea on completion of treatment than patients who did not exercise.  Following their 
Cochrane review on the effect of herbal medicines on CRTs in patients with CRC, Wu et al. (2008) 
concluded that patients receiving Huangqi decoctions were less likely to develop CINV. However, the 
available studies were limited and of low quality. Only one study (Chou et al., 2007) addressed self-
care strategies for nausea4.  
A number of cancer organisations developed CPGs/EBRs on CINV, including the ONS (Tipton et al., 
2007, ONS, 2014), ESMO/MASCC (Roila et al., 2010), ASCO (Basch et al., 2011), UKONS (2013), and 
the NCCN (2014) (Table 5).  CINV protocols were available from five clinical sites. Self-care advice 
only, was provided by a sixth site. In general, CPGs/EBRs focused more on the prevention and 
management of CINV than on assessment although the UKONS (2013) guideline did address 
assessment. The local protocols highlighted the importance of identifying the extent of the CINV, as 
well as the patients’ hydration and nutritional status with a view to determining the grade of CINV 
and the subsequent action required.  General agreement existed across the CPGs/EBRs and local 
protocols that CINV prevention is the first step. Similarly, the approach to treatment based on the 
emetogenic potential of the cytotoxic regimens is broadly consistent. For example, with the 
exception of UKONS, which did not focus on specific pharmacological treatments, all of the other 
organisations advocated that patients receiving highly emetic chemotherapy (HEC) regimens should 
receive the three-drug combination of a neurokinin 1 (NK1) antagonist, 5-hydroxytryptamine-3 (5-
HT3) receptor antagonist and dexamethasone with/without a benzodiazepine. According to the 
NCCN guideline (2014), an olanzapine based regimen may be considered as an alternative in this 
context. In terms of advice and self-care, general agreement existed around the importance of 
reviewing the prescribed anti-emetic regime with patients and counselling them regarding hydration 
and nutrition. The ONS (2007, 2014), ESMO/MASCC (2010) and three clinical sites guidelines 
suggested the potential benefit of non-pharmacological therapies such as relaxation/progressive 
muscle relaxation. The guidelines from ESMO/MASCC and ASCO considered the importance of 
approaches such as BT with desensitisation for anticipatory CINV.  
OM  
Two of the papers from the published literature review addressed OM. However, only one focused 
on symptom management. Peterson and colleagues (2009) evaluated the safety and efficacy of high 
 9 
 
and low dose recombinant human intestinal trefoil factor (rhITF) as a topical oral spray for the 
prevention and treatment of OM in patients receiving their first cycle of chemotherapy for CRC. 
According to the authors, high and low dose rhITF significantly reduced the incidence and severity of 
OM with particular improvements observed one to two weeks following treatment initiation. 
However, the low incidence of grade 3 and 4 OM in the study was noted and it was acknowledged 
that the benefits of this intervention could only be inferred for these high risk groups. Only one 
study (Chou et al., 2007) addressed self-care strategies for OM4.  
Five cancer organisations developed CPGs/EBRs for OM, namely, ESMO (Peterson et al., 2011), 
UKONS (2013), MASCC/ISOO (International Society of Oral Oncology) (Lalla et al., 2014), and ONS 
(Harris et al., 2008). Symptom protocols were available from five clinical sites (Table 6). Self-care 
advice only was provided by a sixth site. The symptom protocols addressed the prevention, 
assessment, and management of OM, while the CPGs/EBRs primarily focused on prevention and 
management. The protocols emphasised the importance of conducting a comprehensive assessment 
to identify the severity of OM, the presence of pain and/or other symptoms suggestive of local or 
systemic infection, dehydration, or compromised nutrition. With reference to management, in the 
main, broad agreement existed across the clinical site protocols and the CPGs/EBRs. Nonetheless, 
there were some variations. The use of oral care protocols and good oral hygiene in the context of 
OM was highlighted across all of the guidelines. However, the MASCC/ISOO (2014) guideline noted, 
that based on the available evidence, it is only possible to ‘suggest’ rather than ‘recommend’ the use 
of oral care protocols for OM prevention, while no guideline is recommended for the use of oral care 
protocols for OM treatment. In addition, although saline/sodium bicarbonate mouthwashes were 
recommended by other organisations (ONS, 2008, ESMO, 2011), MASCC/ISOO indicated that no 
guideline has been developed in this context due to insufficient and/or conflicting evidence. Some 
divergence was found with respect to the use of sucralfate mouthwash which is recommended by 
UKONS (2013) and four clinical sites. However, the MASCC/ISOO panel recommended against the 
use of sucralfate mouthwash for OM prevention or treatment based on a lack of benefit identified in 
the studies reviewed. In addition, the ONS and ESMO did not recommend the use of sucralfate for 
OM treatment associated with radiotherapy. Differences in recommendations were not just 
confined to those between international, local, and national guidelines. Although the MASCC/ISOO 
panel ‘suggest’ (p. 1457) that doxepin 0.5% mouthwash may be effective for OM associated pain, the 
ONS assigned this mouthwash to the category of ‘effectiveness not established’.   
CIPN 
Only three of the papers from the published literature review addressed symptom management and 
one explored self-care strategies for CIPN. Wang et al. (2007) reported that oral glutamine 
significantly reduced CIPN incidence and severity in patients receiving oxaliplatin for metastatic CRC. 
However, following a literature review, Amara (2008) concluded that more high quality RCTs were 
needed to assess the safety and efficacy of oral glutamine before it could be recommended for CIPN 
prevention in patients receiving either high dose paclitaxel or oxaliplatin. Focusing only on 
premenopausal patients with BC, Loprinzi et al. (2008) noted the dearth of literature on effective 
treatments for CIPN.  
Speck et al. (2012) reported that various self-care strategies were employed by women with BC to 
manage CIPN. While it was not possible to establish their effectiveness, the authors reported that 
patients focused on exercise, mindfulness, occupational therapy, and environmental planning to 
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manage their CIPN. Although not described, Chou et al. (2007) noted that self-care strategies were 
used for CIPN by participants in their study4.  
Three cancer organisations developed CPGs/EBRs relevant to CIPN, namely, EONS (2012), ASCO 
(Hershman et al., 2014) (focused on adult cancer survivors) and ONS (Aiello-Laws et al., 2009, ONS, 
2014) (Table 7). A symptom management protocol for CIPN was only available from one clinical site 
and this protocol focused primarily on assessment as it was developed for telephone triage. All of 
the CPGs/EBRs focused more on CIPN management than assessment although EONS outlined some 
important considerations for assessment. No agent was recommended for CIPN prevention. 
However, for CIPN treatment, ASCO (2014) suggested that clinicians ‘may offer’ (p.23) duloxetine 
while the ONS considered duloxetine as ‘likely to be effective’. ASCO, ONS, and EONS all identified a 
number of agents which should not be used for either the prevention or treatment of CIPN based on 
the evidence to date. However, given the limited options for managing CIPN, ASCO noted that some 
agents such as tricyclic antidepressants (TCAs) and gabapentin may be reasonable to try in selected 
patients following a discussion regarding the research to date, benefits, harms, costs, and patient 
preferences. 
Diarrhoea  
None of the articles from the published literature review addressed symptom management 
interventions or self-care strategies for diarrhoea (as a primary outcome) in patients receiving 
chemotherapy for any of the cancers. In contrast, diarrhoea was well addressed in the grey 
literature. Both ONS (Muehlbauer et al., 2009, ONS, 2014) and UKONS (2013) developed guidelines 
for diarrhoea, while protocols for diarrhoea were available from five clinical sites (Table 8). An 
additional clinical site provided self-care information only. UKONS addressed the initial assessment 
and management when patients present with diarrhoea as an emergency/unplanned admission.  
The ONS (2009, 2014) EBR identified interventions for both chemotherapy and radiotherapy-induced 
diarrhoea. Although the level of detail varied across the international and local guidelines, in 
general, consistency was found with reference to diarrhoea assessment and management. More 
specifically, all of the guidelines convey the importance of doing a comprehensive history to 
ascertain the extent of the diarrhoea, associated symptoms, hydration status, and treatment to date 
in order to determine the grade of diarrhoea and the subsequent action required. Loperamide was 
recommended for diarrhoea management across all of the guidelines and the importance of 
adherence was emphasised. The use of octreotide was recommended by both UKONS and ONS and 
three of the clinical sites protocols. However, although codeine phosphate was identified by UKONS 
(2013) and five clinical site protocols as a treatment for diarrhoea, it was not identified by ONS 
(2009, 2014) as an intervention that is ‘recommended for practice’, ‘likely to be effective’ or under 
‘expert opinion’. Also, ONS assigned budesonide to the ‘effectiveness not established’ category. 
However, budesonide does feature in the protocols of four clinical sites for the treatment of severe 
diarrhoea. In relation to self-care, broad agreement was found regarding the recommendations for 
hydration and nutrition.  
Constipation 
The published literature search located no articles on symptom management interventions for 
constipation (as a primary outcome) in patients receiving chemotherapy for any of the cancers. Only 
one study (Chou et al., 2007) addressed self-care strategies for constipation4.  
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Only a limited number of guidelines and symptom protocols were available for constipation. These 
documents included the UKONS (2013) guideline for the initial management of constipation in 
patients who present as an emergency/unplanned admission and the ONS (Woolery et al., 2008, 
ONS, 2014) EBR for the prevention and management of constipation (Table 9). Only one clinical site 
provided a symptom protocol (telephone triage) for constipation, although information on self-care 
for this symptom was available from three additional sites. The guidance from ONS (2008) and 
UKONS (2013) and the clinical site protocol are broadly consistent with respect to constipation 
assessment. Likewise, the guidance for constipation management (including self-care) was similar. 
Specific information included the importance of a high fibre diet, adequate hydration, and 
adherence to prescribed medications. ONS (2008, 2014) identified a number of interventions that 
were considered to be ‘likely to be effective’ particularly in the context of opioid-induced 
constipation. 
PPE 
None of the articles retrieved through the published literature review addressed symptom 
management interventions or self-care strategies for PPE (as a primary outcome) in patients 
receiving chemotherapy for any of the cancers. No international CPGs were available for PPE. 
However, the ONS (2014) included this symptom in its EBR on skin reactions. The UKONS (2013) 
guideline focused on the initial management of patients with PPE who present as an 
emergency/unplanned admission (Table 10). A symptom management protocol for PPE was only 
available from one clinical site and this protocol focused on management only. The UKONS (2013) 
guideline recommended the provision of reassurance and reinforcing the importance of the skin 
care regime to patients experiencing grade 1 PPE while advising to withhold treatment for higher 
grade PPE.  Consideration of pyridoxine was recommended by both UKONS and the clinical site 
protocol. However, this medication was assigned to the category of ‘not recommended for practice’ 
by ONS.  
 
FN and/or infection  
FN and infection are discussed together in this context given their close relationship and the limited 
number of studies identified for either toxicity. The published literature search located two review 
papers related to these toxicities. One paper focused on the use of supportive therapies for the 
management of FN and infection. A second paper discussed the evidence to date for Chinese herbal 
medicines (CHMs) for CRTs including leucopenia. O’Shaughnessy et al. (2007) discussed the use of 
colony stimulating factors (G-CSF) in patients receiving adjuvant treatment for BC. Based on the 
cumulative evidence across a number of different cancers, the authors pointed to the recent NCCN 
and ASCO guidelines which recommended routine use of CSFs for all patients receiving curative 
chemotherapy associated with a ≥20% risk of FN or in high risk patients receiving curative 
chemotherapy associated with a ≤20% risk of FN. Following their Cochrane review which examined 
the effect of CHMs on CRTs in patients with CRC, Wu et al. (2008) concluded that extracts containing 
Huangqi had favourable effects on white blood cells, with respect to both total counts and in speciﬁc 
subcategories of immunocompetent lymphocytes. However, the available studies were limited and 
of low quality. None of the studies addressed self-care for FN or infection. 
 
A number of CPGs/EBRs were available for FN and infection (Table 11). ASCO (Smith et al., 2006, 
Flowers et al., 2013) published guidelines on the use of CSFs and the antimicrobial prophylaxis and 
 12 
 
outpatient management of FN, respectively. Each year, the NCCN updates its guidelines for the 
prevention and treatment of cancer-related infections and their recommendations for myeloid 
growth factors. ESMO published guidelines for the management of FN (de Naurois et al., 2010) and 
the use of CSFs (Crawford, Caserta and Roila, 2010). Finally, ONS produced an EBR of interventions 
to prevent cancer-related infections (Zitella et al. 2006, ONS, 2014). The UKONS (2013) guideline 
focused on the initial assessment and management of patients presenting with neutropenic sepsis. 
Symptom protocols were developed by the clinical sites for the assessment and management of FN 
and/or neutropenic sepsis (Table 11). Overall, the guidance across all of these guidelines and 
protocols is consistent for both the assessment and management of patients presenting with 
FN/suspected neutropenic sepsis. All of the guidelines conveyed the importance of a comprehensive 
history and assessment and the administration of appropriate treatment based on the risk category 
identified. Broad consistency existed with respect to the prophylactic measures recommended for 
infection prevention. 
Pain  
Two papers from the published literature review focused on symptom management interventions 
for cancer pain. Both papers address exercise for pain in women receiving treatment for BC. 
Following their SR, Tatham and colleagues (2013) concluded that exercise may decrease shoulder 
pain related to BC treatment. However, they noted that more high quality studies were needed. Due 
to the limited detail in the studies reviewed, the authors could only infer that a ‘multi-factorial’ 
(p.329) exercise programme may be beneficial. Following their multicentre RCT that examined the 
impact of exercise on physical functioning and symptoms such as ‘bodily pain’ (p.1823), Courneya et 
al. (2013) reported that a higher dose (50-60 minutes) of aerobic exercise was more beneficial for 
managing bodily pain associated with adjuvant BC treatment than either standard doses (25-30 
minutes) or a combined dose of 50 to 60 minutes of aerobic and resistance exercise. Only one study 
(Chou et al., 2007) addressed self-care strategies for pain4.  
 
Cancer pain is well addressed in the grey literature. Guidelines focusing on cancer pain were 
available from ESMO (Ripamonti et al., 2012), EONS (2012), ONS (Aiello-Laws et al., 2009, ONS, 
2014) and NCCN (2014) (Table 12). Only one clinical site provided a pain management protocol. As 
this protocol was developed for telephone triage, its primary focus was pain assessment rather than 
pain management interventions (Table 12). Brief self-care advice was available from another clinical 
site. A general consensus was found across all of the international guidelines regarding the approach 
to pain assessment and management. More specifically, the guidelines highlighted the importance 
of undertaking a comprehensive history and assessment to examine the physical and psychosocial 
impact of pain. Many factors require consideration in order to determine the most appropriate 
interventions including but not exclusive to the type and severity of pain, whether it is acute, 
chronic, or breakthrough pain, the patient’s diagnosis and treatment to date, comorbidities and 
psychosocial factors. Recommendations included the use of both pharmacological and non-
pharmacological strategies and the importance of managing common side effects such as 
constipation and nausea and vomiting. These guidelines were broadly in line with the World Health 
Organisation (WHO) analgesic ladder which advocates a sequential progression from non-opioids to 
weak opioids to strong opioids. However, while acknowledging that the WHO ladder has served as 
an excellent teaching tool, NCCN suggested the use of opioids for all levels of pain including mild 
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pain. The importance of providing psychosocial support and education to the patient and family was 
recommended. 
 
Discussion  
 
To our knowledge this scoping review is the first of its kind to examine the literature and 
international, national, and relevant local guidelines for the assessment and management of the 
most common CRTs, namely, fatigue, nausea, vomiting, OM, CIPN, diarrhoea, constipation, FN, 
infection, PPE, and pain in people with BC, CRC, NHL, or HL. A number of observations are evident 
from this review. Of all of the symptoms included in the review, fatigue is the most frequently 
studied with over half of the published articles addressing this symptom. However, the papers 
primarily focused on fatigue in women with BC. Only one study (Courneya et al., 2009) examined the 
impact of exercise in patients with lymphoma. With the exception of self-care (Spichiger et al. 2012), 
none of the studies examined interventions for fatigue in patients with CRC. Given the benefits of 
exercise identified in the studies of BC in this review and more recently (Mishra et al., 2014), similar 
studies in patients with CRC and lymphomas are warranted. In the meantime, given the relatively 
low engagement in exercise among oncology patients receiving chemotherapy (Spichiger et al., 
2012) and among cancer survivors (Forbes et al., 2015), clinicians should counsel patients on the 
benefits of exercise as tolerated.  
The use of aerobic and resistance exercises are supported by ASCO, ONS, and NCCN as interventions 
for fatigue. The other interventions supported by these organisations and the published literature 
(Wanchai et al., 2011) include the management of associated symptoms and treatable factors, 
education and counselling, energy conservation measures, CBT/BT, sleep therapy, 
psychoeducational therapies, CT, and nutritional advice. However, it is likely that these interventions 
are only effective if assessment and management of fatigue is undertaken regularly throughout 
patients’ treatment and not just at the outset (Spichiger et al., 2012). While we cannot confirm that 
the lack of protocols from the clinical sites necessarily indicates that fatigue assessment and 
management is not ongoing, it does suggest that this symptom may not be prioritised to the same 
extent as others for which protocols do exist. If this is the case, it needs to be redressed given that 
fatigue is one of the most frequently reported CRTs (Goldstein et al., 2012, Wang et al., 2014) and is 
associated with significant morbidity and utilization of healthcare resources (Goldstein et al., 2012). 
In contrast to fatigue, CINV was more likely to be addressed by clinical site protocols than the 
published literature. Both nausea and vomiting are well addressed by CPGs/EBRs including ONS, 
ESMO/MASCC, ASCO and NCCN guidelines. General consensus exists across these guidelines with 
respect to the anti-emetics recommended, with all of the organisations recommending that patients 
receiving HEC should receive a similar three-drug combination of anti-emetic therapy. The self-care 
measures recommended in the clinical site protocols are broadly consistent with those in the CPGs.  
Only two papers in the review of the published literature focused on OM. However, OM guidelines 
are available from a number of cancer organisations and clinical sites. While a general consensus 
was found across all of the guidelines and protocols with respect to the assessment, management, 
and prevention of OM, some differences were identified in the recommendations. Although the 
MASCC/ISOO (2014) panel do not actively recommend against the use of oral care protocols or 
saline/sodium bicarbonate mouthwashes, they appear less compelled by the evidence for these 
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interventions for the prevention of OM across all cancer treatments. However, the MASCC/ISOO 
(2014) panel did recommend against the use of sucralfate mouthwash for the prevention or 
treatment of OM. In addition, the ONS (2008, 2014) recommended against the use of sucralfate as 
did ESMO for the treatment of OM associated with radiotherapy. Clinical protocols from four clinical 
sites and the UKONS (2013) guideline on OM suggest that sucralfate was still recommended for OM. 
As the international guidelines were published more recently, it is conceivable that national and 
local protocols had not been updated to reflect these recommendations. Differences in 
recommendations were not just confined to those between international, national and local 
guidelines as evidenced by the differing recommendations from MASCC/ISOO and the ONS on the 
effectiveness of doxepin 0.5% mouthwash for OM associated pain. While differing conclusions may 
be based on the availability of data at the time of the respective guideline publications, it does 
underscore the challenges encountered by clinicians when updating local protocols. 
CIPN was the subject of three papers in the review of the published literature. However, more 
studies are needed to identify effective approaches to prevent and manage this CRT. Although 
CPGs/EBRs were available from three international organisations, a CIPN symptom protocol was 
available from only one clinical site.  Again, this finding may be due to the fact that the CPGs/EBRs 
are more recent. It may reflect the limited options available for the prevention and/or treatment of 
CIPN. In addition to duloxetine, ASCO suggested that TCAs and gabapentin may be reasonable to try 
in selected patients. The EONS (2012) guideline may be of particular benefit to oncology nurses for 
the purpose of educating patients about beneficial CIPN self-care strategies.  
The published literature search located no papers focused on symptom management for diarrhoea, 
constipation, or PPE. Although diarrhoea is addressed by only ONS (2009, 2014) and UKONS (2013), 
symptom protocols for diarrhoea were provided by five clinical sites. In general, consensus was 
found across the guidelines and local protocols with respect to diarrhoea assessment and 
management. These recommendations were consistent with the guideline published by ASCO 
(Benson et al., 2004). Two particular differences were noted among the local and national guidelines 
when compared to the ONS recommendations.  Although codeine phosphate was identified by 
UKONS and the five clinical site protocols as a treatment for diarrhoea, it was not identified as an 
intervention for diarrhoea by ONS (2009). Also, in 2009, ONS assigned budesonide to the 
‘effectiveness not established’ category. However, this medication features in the symptom 
management protocols of four clinical sites for the treatment of severe diarrhoea. This review found 
a limited number of guidelines and symptom protocols available on constipation. Only one clinical 
site provided a symptom protocol although information related to self-care for constipation was 
available from four clinical sites. Similarly, a dearth of CPGs/EBRs focused on symptom management 
for PPE and perhaps not unrelated a symptom management protocol was provided by only one 
clinical site. Of note, consideration of pyridoxine was recommended by both UKONS (2013) and a 
clinical site protocol. However, this medication was assigned to the category of ‘not recommended 
for practice’ by the ONS.  
FN and infection was the subject of only two papers from the published literature review. Both 
papers were literature reviews and one was a Cochrane review (Wu et al., 2008). This finding is likely 
due to the inclusion criteria which focused exclusively on the symptom management and self-care 
strategies for FN and infection in patients diagnosed with BC, CRC, NHL, or HL.  Most likely reflecting 
the potentially life threatening nature of infection in patients with cancer (Pathak et al., 2015), a 
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number of CPGs/EBRs address FN and infection.  Symptom protocols were developed by the clinical 
sites and, in the main, the guidance across all of these guidelines and protocols is consistent for both 
the assessment and management of patients presenting with FN/suspected neutropenic sepsis. The 
guidelines all conveyed the importance of a comprehensive history and assessment and the delivery 
of appropriate treatment based on the risk category identified. Broad consistency was found with 
respect to the prophylactic measures recommended for infection prevention.  
The review of the published literature located two papers on symptom management interventions 
for pain. Both papers focused on exercise for pain in women receiving treatment for BC and while 
this intervention appears promising, more high quality studies are needed. Overall, pain is well 
addressed by CPGs/EBRs. In contrast to this finding, only one clinical site provided a symptom 
management protocol for pain. As this protocol was developed for the purpose of telephone triage, 
a greater focus was placed on the assessment of pain rather than interventions for pain 
management. Brief self-care advice was available from another clinical site. A general consensus was 
found across all of the international guidelines regarding the approach to pain assessment and 
management. Recommendations included the use of both pharmacological and non-
pharmacological strategies and the importance of managing common side effects.  The guidelines 
are broadly in line with the World Health Organisation (WHO) analgesic ladder which advocates a 
sequential progression from non-opioids to weak opioids to strong opioids. However, more recently 
the NCCN (2014) suggested the use of opioids for all levels of pain including mild pain. The 
importance of providing psychosocial support and education to the patient and family was 
recommended. 
Limitations 
 
The main limitation of this review is the lack of empirical research retrieved for the assessment and 
management of diarrhoea, constipation and PPE, in particular. This deficit may be due to the fact 
that the published literature search was confined to those studies where symptom assessment, 
management, or self-care was identified as a primary outcome. In addition, limiting the search to 
three databases and including only those studies published in English and undertaken over the 
previous ten year period (2004-2014) may explain the dearth of studies for these symptoms.  The 
conduct of a recent literature review3 and time constraints imposed by internal study deadlines 
informed the decision to limit the search to three databases and to include only those studies 
conducted in the previous ten years. That said, this scoping review includes seven literature reviews 
(including four SR) and recently updated CPGs/EBRs from leading international medical and nursing 
cancer organisations. The studies included in this review were not critically appraised as a scoping 
review does not set out to determine the quality of evidence, rather it seeks to examine as 
comprehensively as possible the published and grey literature relevant to the research question 
(Arksey and O’ Malley, 2005). Finally, information on symptom management protocols and self-care 
guidance was available from just over 40% of the participating clinical sites. Of note, while this 
scoping review included a consultation exercise with clinicians and patients at each of the 
participating clinical sites and with clinicians working with National Health Service (NHS) 24) 
(Scotland’s national telehealth and telecare organisation), the data from this exercise are not 
reported here due to the word count limit. 
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Conclusions 
Guidance for symptom management of the most common CRTs varies across the published and grey 
literature. A need exists for more empirical research on symptom management for PPE, diarrhoea, 
constipation and CIPN. In addition, empirical research studies of symptom management 
interventions are needed in patients with CRC and lymphomas. Finally, research is needed on the 
efficacy of self-care strategies in patients with BC, CRC, HL and NHL. Relative to other symptoms, 
PPE, diarrhoea, and constipation are less likely to be addressed by CPGs/EBRs. With a few 
exceptions, a broad consistency exists across CPGs/EBRs and local guidelines on the assessment and 
management of commonly occurring CRTs.    
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Appendix 1 
String 1 
Assessment OR evaluation OR measurement OR tool OR questionnaire OR "outcome measure" OR 
"symptom management" OR "symptom control" OR "Symptom Assessment"[Mesh] OR "Outcome 
and Process Assessment (Health Care)"[Mesh] OR "Self-Assessment"[Mesh]) OR "Evaluation 
Studies as Topic"[Mesh] OR "Questionnaires"[Mesh] OR "Outcome Assessment (Health 
Care)"[Mesh] OR “patient reported outcome measur$” 
String 2  
"BC" OR "breast tumor" OR "colorectal cancer" OR "colon cancer" OR "rectal cancer" OR 
lymphoma OR "non-Hodgkin lymphoma" OR "Hodgkin's disease" OR "Breast Neoplasms"[Mesh] 
OR "Colorectal Neoplasms"[Mesh] OR "Colonic Neoplasms"[Mesh] OR "Rectal Neoplasms"[Mesh] 
OR "Lymphoma"[Mesh] OR "Lymphoma, Non-Hodgkin"[Mesh] OR "Hodgkin Disease"[Mesh] 
String 3  
Chemotherapy OR chemotoxicity OR cytotoxic agents OR treatment regiment OR "Drug 
Therapy"[Mesh] OR "drug therapy" [Subheading 
String 4 
Self-care OR self-management OR self-efficacy OR self-assessment OR "Self Care"[Mesh] OR "Self 
Efficacy"[Mesh] OR "Self-Assessment"[Mesh] 
String 5  
Chemotherapy AND (symptom* OR side effect* OR adverse effect*) OR Nausea OR vomiting OR 
diarrhea OR constipation OR Stomatitis OR oral mucositis OR peripheral neuropathy OR 
alterations in sensation OR hand-foot syndrome OR febrile neutropenia OR fever OR infection OR 
fatigue OR tiredness OR exhaustion OR pain OR "Peripheral Nervous System Diseases"[Mesh] OR 
"Hand-Foot Syndrome"[Mesh] OR "Febrile Neutropenia"[Mesh] OR "Chemotherapy-Induced 
Febrile Neutropenia"[Mesh] OR "Fever"[Mesh] OR "Infection"[Mesh] OR "Fatigue"[Mesh] OR 
"Pain"[Mesh] OR "Nausea"[Mesh] OR "Stomatitis"[Mesh] 
Final Search  
 
chemotherapy AND (symptom* OR side effect* OR adverse effect*) OR nausea OR vomiting OR 
diarrhea OR constipation OR stomatitis OR oral mucositis OR peripheral neuropathy OR 
“alterations in sensation” OR hand-foot syndrome OR “febrile neutropenia” OR fever OR infection 
OR fatigue OR tiredness OR exhaustion OR pain OR "Peripheral Nervous System Diseases"[Mesh] 
OR "Hand-Foot Syndrome"[Mesh] OR "Febrile Neutropenia"[Mesh] OR "Chemotherapy-Induced 
Febrile Neutropenia"[Mesh] OR "Fever"[Mesh] OR "Infection"[Mesh] OR "Fatigue"[Mesh] OR 
"Pain"[Mesh] OR "Nausea"[Mesh] OR "Stomatitis"[Mesh] AND "BC" OR "breast tumor" OR 
"colorectal cancer" OR "colon cancer" OR "rectal cancer" OR lymphoma OR "non-Hodgkin 
lymphoma" OR "Hodgkin's disease" OR "Breast Neoplasms"[Mesh] OR "Colorectal 
Neoplasms"[Mesh] OR "Colonic Neoplasms"[Mesh] OR "Rectal Neoplasms"[Mesh] OR 
"Lymphoma"[Mesh] OR "Lymphoma, Non-Hodgkin"[Mesh] OR "Hodgkin Disease"[Mesh] AND 
assessment OR evaluation OR measurement OR tool OR questionnaire OR "outcome measure" OR 
"symptom management" OR "symptom control"OR "Symptom Assessment"[Mesh] OR "Outcome 
and Process Assessment (Health Care)"[Mesh] OR "Self-Assessment"[Mesh] OR "Evaluation 
Studies as Topic"[Mesh] OR "Questionnaires"[Mesh] OR "Outcome Assessment (Health 
Care)"[Mesh] AND chemotherapy OR chemotoxicity OR cytotoxic agents OR treatment regimens 
OR "Drug Therapy"[Mesh] OR "drug therapy"[Subheading] AND self-care OR self-management OR 
self-efficacy OR self-assessment OR "Self Care"[Mesh] OR "Self Efficacy"[Mesh] OR "Self-
Assessment"[Mesh] 
 
Figure 1. Example of database search (PubMed) 
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Appendix 2 
Table 2. Description of published papers (N=27) included in review  
Author/Year Sample size/Diagnosis Study Design* Study Aim/Intervention/Instrument Study Findings and Limitations  
Fatigue  
Berger et al. 
(2009): 
 
N=219; patients with 
stages 1 to 111 BC 
commencing adjuvant 
chemotherapy.  
RCT (Two 
centres) 
 (B1) 
To determine one year outcomes of a four 
component behavioral therapy (BT) sleep 
intervention vs a healthy eating control (HEC) on 
fatigue (primary endpoint). 
BT plan including stimulus control, modified sleep 
restriction, relaxation therapy, and sleep hygiene. 
Instrument(s): Piper Fatigue Scale 
BT (Individualized Sleep Promotion Plan 
[ISPP ©]) improved global sleep quality but 
did not impact fatigue outcomes.  
Limitations: milder fatigue levels than 
anticipated possibly restricting the range 
required to observe significant differences 
between groups. 
Courneya et 
al. (2007a): 
N=242; patients with 
stages 1 to 111A BC, 
commencing adjuvant 
chemotherapy 
Multicentre 
RCT (B1) 
To evaluate impact of supervised aerobic exercise 
training (AET) and resistance exercise (RET) vs usual 
care on fatigue (secondary endpoint).  
Instrument(s): Functional Assessment of Cancer 
Therapy-Anemia scale (FACT-An). 
Neither AET or RET significantly improved 
fatigue, yet positive trends noted for the 
exercise groups.  
Limitations:  70% adherence, 33% 
recruitment rate and ethnically 
homogenous sample.   
Courneya et 
al. (2007b): 
N=242; patients with 
stages 1 to 111A BC 
commencing adjuvant 
chemotherapy. 
Six-month follow up 
data obtained from 201 
participants 
Multicentre 
RCT (B1) 
Six-month post-intervention follow-up of (2007a) 
study evaluating impact of aerobic exercise training 
(AET) and resistance exercise intervention (RET) on 
fatigue (secondary endpoint). 
Instrument(s): FACT-An 
 
Participants who indicated adherence to 
both AET and RET during follow-up period 
reported improved levels of fatigue 
(p=.013).  
Limitations: reliance on self-reporting, 
differential loss to follow-up amongst 
groups and failure to acquire follow up 
data of objective end points.  
Courneya et 
al. (2009): 
 
N=122; patients with 
HL or NHL receiving 
chemotherapy or no 
treatments 
Single centre 
RCT (B1)  
To evaluate impact of 12 weeks of supervised AET vs 
usual care (UC) on physical functioning and on 
fatigue (secondary endpoint).  
Instrument(s): FACT-An fatigue subscale 
 
At post-intervention, fatigue levels in the 
AET group were better than in UC group 
(p=.013).  
Limitations: sample heterogeneity, limited 
power to determine subgroup effects, 
short duration of intervention, 25% 
recruitment rate. 
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Goldstein et 
al. (2012): 
N=218; patients with 
stage 1 or 11 BC post-
surgery commencing 
adjuvant treatment 
(chemotherapy, 
radiotherapy, chemo-
radiotherapy or 
endocrine therapy). 
Five year 
prospective 
cohort study 
(B3) 
To examine the early natural history of cancer 
related fatigue (CRF) including incidence and 
predictors. 
Instrument(s): Somatic and Psychological Health 
Report (SPHERE) 
Case rate for fatigue was 24% after surgery 
and 31% at end of treatment, although it 
was persistent for some at 6 months (11%) 
and 12 months (6%). Persistent CRF 
predicted by tumour size. CRF associated 
with significant disability and healthcare 
utilization. 
Limitations: not all patients participated in 
the main cohort and estimate of incidence 
at 5 years was cross-sectional and did not 
assess potential confounding clinical 
factors such as cancer recurrence. 
Ligibel et al. 
(2010): 
 
N=41; patients with 
stage 1-111 BC 
receiving adjuvant or 
neoadjuvant 
chemotherapy and/or 
radiation therapy. 
 
Single-arm 
pilot study 
(B3)       
 
To evaluate changes in exercise behaviours. 
Secondary aim: assessment of changes in fatigue 
following a home-based, 12-week moderate-
intensity aerobic exercise intervention. Exercise 
counselling via telephone. 
Instrument(s): EORTC QLQ C-30. 
Trend towards improvements in fatigue 
(p=.08).  
Limitations:  small single arm pilot study. 
Differences in chemotherapy and 
radiotherapy completion time-frame 
limiting ability to confidently assert that 
decreases in fatigue were due to exercise 
intervention rather than treatment 
completion.  
Munir et al., 
(2011):                        
 
N=31; patients with 
stage 1-111 BC 
commencing adjuvant 
chemotherapy 
 
Mixed 
methods 
study (B3) 
 
 
To explore what healthcare information and 
supports are available to assist patients to 
understand the effects of chemotherapy on daily 
functioning at home and work.  
Primarily focused on cognitive problems. 
Semi-structured interviews explored changes in and 
impact of fatigue. 
Instrument(s): Fatigue Severity Scale 
Intervention validation questionnaire 
 
Self-reported fatigue experienced by 
majority and increased across the study 
period (p≤.001). Subjective cognitive 
functioning positively correlated with 
fatigue (<.05). All received information 
regarding effects of treatment related 
fatigue. 
Limitations: small exploratory study based 
at one clinical site. Did not control for type 
of chemotherapy or surgery variables. 
Potential participant self-selection.  
Spichiger et 
al. (2012): 
N=19; patients 
receiving 
Qualitative 
study (B3) 
To explore patients perspectives of fatigue, with 
particular focus on communication with healthcare 
Reported receiving minimal fatigue 
management support after initial 
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chemotherapy for any 
stage of breast, 
colorectal, or lung 
cancer or lymphoma 
 
employing 
‘aspects’ of 
Grounded 
Theory 
professionals (HCPs), self-care activities and the 
perceived effectiveness of both. 
Interviews conducted with patients after third 
chemotherapy cycle. 
information provided by HCPs.  Various 
intuitive self-care approaches employed 
including rest but difficulty explaining 
rationale for or effectiveness of chosen 
measures.  
Adequate and systematic information 
provision needed along with continuous 
assessment. 
Limitations: recruitment in one hospital, 
small sample size; data saturation 
(although not sought) was not achieved. 
Wanchai et 
al. (2011): 
 
28 eligible studies 
focusing on BC (BC) 
during treatment 
(n=19, 68%), and BC 
survivors post-
treatment (n=9, 32%) 
 
 
Systematic 
review (A2)  
 
(75% RCTs, 
25% quasi-
experimental) 
To critically review literature on non-
pharmacological supportive strategies for patients 
experiencing CRF. Search conducted on MEDLINE 
and CINAHL databases. 
Included papers published in English from 2000-
2010.  
Instrument(s): Both unidimensional and 
multidimensional assessment tools used in reviewed 
studies. 
 
Exercise (both home based and supervised) 
and other strategies promoting exercise 
may positively impact on CRF. Other 
strategies likely to be effective include 
education and counselling, sleep therapy 
(incorporating, stimulus control, sleep 
restriction and sleep hygiene) and 
complementary therapies (CT) such as 
polarity therapy (energy healing), tai chi 
and restorative yoga although further 
research is needed for CT.  
Limitations related to methodological 
weaknesses in some of the studies 
reviewed.  
Wu et al. 
(2008) 
 
N=98; patients with BC 
receiving 
chemotherapy 
Secondary 
data analysis  
of a large, 
single blind, 
multicentre 
RCT (B3) 
To examine daily fatigue patterns during third cycle 
of chemotherapy and determine if fatigue 
trajectories differ based on exercise or 
chemotherapy modality. Original study tested the 
effectiveness of a systematic exercise intervention 
on fatigue 
Instrument(s): Daily fatigue diary incorporating a 
numeric rating scale; Surgeon General’s Guideline 
for Physical Activity (US DHHSa, 1996) 
Patterns of change in fatigue levels did not 
differ between exercisers and non-
exercisers, yet non-exercisers reported 
higher fatigue levels throughout the third 
cycle of chemotherapy.  
Limitations:  homogenous sample, absence 
of baseline measurement for comparison 
and acknowledgment that daily diary may 
not fully reflect symptom experience.  
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Oral mucositis (OM) 
Peterson et 
al. (2009): 
N=99; patients with 
stage 1-1V colorectal 
cancer who 
experienced oral 
mucositis (OM) (WHO 
≥grade 2) while 
receiving the first cycle 
of chemotherapy 
(primary treatment 
modality) 
Multicentre 
RCT (B1) 
To evaluate the safety and efficacy of high dose and 
low dose recombinant human intestinal trefoil factor 
(rhITF) vs placebo as a topical oral spray for the 
prevention and treatment of OM.  
Instrument(s): WHO OM Grading Scale and Oral 
Mucositis Assessment Scale (OMAS) 
High dose rhITF and low dose rhITF 
significantly reduced the incidence and 
severity of OM. Particular benefit was 
observed 7-14 days after commencement 
of chemotherapy. 
Limitations: small sample size which likely 
resulted in the low frequency of grade 3-4 
mucositis, therefore; the impact of rhITF in 
this higher-risk group can only be inferred.  
Nausea 
Lee et al. 
(2008) 
 
N=112; patients with 
stages 1 to 111 BC 
commencing their first 
cycle of adjuvant 
chemotherapy 
 
Secondary 
data analysis 
of a 
longitudinal, 
multicentre, 
RCT (tested 
the 
effectiveness 
of a 
systematic 
exercise 
intervention  
for CRF and 
associated 
symptoms 
including 
nausea) (B3) 
To determine the relationship between nausea 
intensity and a moderate level of aerobic exercise 
during and after adjuvant cancer treatment.  
Instrument(s): Nausea intensity (0-10 numeric scale), 
exercise status and Karnofsky Performance Scale 
(KPS) were measured through patient self-report. 
Data collected at three time-points. 
 
 
 
Although generally low for all participants, 
nausea intensity was lower for exercisers 
than for non-exercisers (p=.03) at T2 (end 
of adjuvant chemotherapy) while baseline 
(T1) and end of study (T3) nausea intensity 
scores did not differ significantly between 
the groups. 
Limitations: unidimensional measurements 
of nausea, infrequent exercise status 
measurements, non-measurement of 
nausea intensity during chemotherapy and 
inability to determine if T1 nausea was 
anticipatory or delayed.  
Vomiting 
Dibble et al. 
(2004) 
 
N=303; Patients 
receiving 
chemotherapy for BC  
Multicentre 
longitudinal 
descriptive 
study (B3) 
To describe the incidence and intensity of 
chemotherapy induced vomiting (CIV) for BC since 
the advent of 5-HT3 antagonists.  
Instrument(s): Daily log consisting of the three-item 
Despite the use of 5-HT3 antagonists, both 
acute and delayed CIV continue to be a 
problem for some BC patients (younger 
age, higher BMI, minority women). 
 28 
 
vomiting experience 
subscale from Rhodes Index of Nausea, Vomiting 
and Retching (INVR) 
Demographic and clinical questionnaires 
 
Although likely to be beneficial for those 
experiencing more CIV, few medication 
changes (8%) were made between cycles. 
Limitations: study sites may have been 
those where vomiting was a particular 
problem, participants only followed over 
two cycles of chemotherapy. Note: study 
undertaken prior to use of neurokinin 1 
receptor antagonists.   
Nausea and Vomiting 
Fernandez-
Ortega et al. 
(2012): 
N=160; patients 
receiving moderate to 
highly emetogenic 
chemotherapy  for 
various types of cancer 
including  breast (44%) 
and colorectal (6.2%) 
cancers 
Open 
multicentre 
observational 
study (B3) 
To analyse the impact of chemotherapy induced 
nausea and vomiting (CINV) associated with 
moderate/highly emetogenic chemotherapy on 
patients QoL. 
Instrument(s) Patient diary, Visual Analog Scale 
(VAS) (nausea), functional living index-emesis (FLIE) 
 
 
Patients receiving high or moderate CINV 
regimens experienced significant nausea 
(31%) and vomiting (45%) despite 
administration of optimal antiemetic 
prophylaxis and both symptoms negatively 
impacted on their QoL. 
Limitations: real incidence of nausea may 
be less as self-administered questionnaire 
may have overestimated this symptom. 
Note: study undertaken prior to use of 
neurokinin 1 receptor antagonists.   
Pain 
Tatham et al. 
(2013): 
 
6 studies (4 RCTs, 2 
Case Series) 
 
Systematic 
review (A2) 
To determine whether exercise therapy is more 
effective than no therapy in reducing shoulder pain 
for women undergoing treatment of BC, as well as to 
identify which exercise type is most effective and 
appropriate outcome measures to assess shoulder 
pain. Searches undertaken in PEDro, CINAHL, 
PubMed, Ovid MEDLINE and AMED, for relevant 
publications up to and including April 2011.  
 
Exercise may be beneficial in reducing 
shoulder pain related to BC treatment but 
more high quality studies are warranted. 
 Valid outcome measures such as the Brief 
Pain Inventory (BPI) and the visual 
analogue scale (VAS) appear effective in 
evaluating patients with shoulder pain and 
monitoring the initial and long-term effects 
of treatment plans.  
Limitations: low number of relevant 
studies and low methodological quality of 
studies.  
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Peripheral Neuropathy (CIPN) 
Amara 
(2008):  
 
3 studies identified 
(Clinical trials)  
 
Literature 
review (A2) 
 
To evaluate the role of glutamine in the reduction of 
chemotherapy induced peripheral neuropathy 
(CIPN). PubMed searched for primary studies (1990 
– May 2008).  
 
Two studies reported that oral glutamine 
was effective in decreasing CIPN associated 
with high dose paclitaxel while another 
study found it effective for CIPN in patients 
with colorectal cancer being treated with 
oxaliplatin.  However, larger, well designed 
placebo controlled RCTs need to be 
conducted. 
Limitations: Non SR conducted through 
PubMed only; also, methodological 
limitations of the studies reviewed. 
Speck et al. 
(2012): 
N=25; patients with BC 
who had received at 
least two cycles of 
taxane-based 
chemotherapy. Either 
currently or within 6 
months  of treatment 
(neoadjuvant, 
adjuvant, metastatic) 
(stratified  to ensure 
half with and without 
documented CIPN) 
Descriptive 
qualitative 
study (B3) 
 
To explore the self-management strategies utilized 
by female BC patients to cope with the impact of 
CIPN.  
Data collected via semi-structured interviews and 
patient level data.  
Various self-management strategies 
employed to manage symptoms of CIPN 
including exercise, mindfulness, 
occupational therapy, and environmental 
planning.  
Limitations: potential for misclassification, 
information bias and issue of 
generalisability.  
Wang et al. 
(2007): 
N=86; patients with 
metastatic colorectal 
cancer (MCRC) 
receiving 
chemotherapy 
 
 
 
RCT (pilot 
study) (B1) 
 
To assess the efficacy of oral glutamine (15g twice a 
day for seven days every two weeks) for preventing 
CIPN in patients receiving oxaliplatin for MCRC.  
Instrument(s): National Cancer Institute Common 
Toxicity Criteria (NCI-CTC) and various neurological 
assessments  
A significantly lower incidence of both 
grade 1-2 CIPN after chemotherapy cycle 2 
(p=.04) and grade 3-4 CIPN after cycles 4 
(p=.05) and 6 (p=.04) in the glutamine 
group. 
Limitations: non-placebo controlled, 
unblinded and relatively small sample size. 
Multiple Symptoms 
Chou et al. N=25; patients Descriptive To explore the cancer symptom experience, self-care On average, participants reported 
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(2007): 
 
receiving a second or 
third cycle of 
chemotherapy for 
cancers of the lung 
(24%), nasopharynx 
(24%), gastrointestinal 
tract (20%), 
ovary/uterus (16%), 
breast (12%), or other 
cancer type (4%).  
exploratory 
cohort Study 
(B3) 
 
strategies, and quality of life (QoL) among first 
generation Chinese Americans. Instrument(s): Suinn-
Lew Acculturation Scale, Memorial Symptom 
Assessment Scale (MSAS), Self-Care Diary, 
Multidimensional QoL Scale–Cancer and Short-Form 
36 Health Survey.  
 
experiencing 14 symptoms weekly and 
used approximately two self-care 
strategies per symptom. Strategies used 
were considered to be low to moderate in 
effectiveness. Approximately 20% used 
Traditional Chinese Medicine.  
Limitations: small sample size in one 
setting and no qualitative data on 
symptom experience.  
Courneya et 
al. (2013): 
 
N=301; patients with 
stages 111C BC 
commencing adjuvant 
chemotherapy 
 
 
Multicentre 
RCT (B1) 
To compare two different doses and types of 
exercise for improving physical functioning/ 
symptom management. Standard dose: 25-30 
minutes of aerobic exercise (STAN) compared to a 
higher dose of supervised exercise (HIGH) (50- 60 
minutes) and a combined dose of 50 to 60 minutes 
of aerobic and resistance exercise (COMB). 
 
Instrument(s): relevant subscales of Medical 
Outcomes Survey Short Form (SF-36) and Functional 
Assessment of Cancer Therapy (FACT)  
Although not superior to standard doses 
on SF-36 physical functioning scale, a 
higher volume of aerobic or combined 
exercise are feasible and safe during BC 
chemotherapy and may be superior to 
standard volumes for managing 
deterioration in physical functioning and 
certain symptoms such as bodily pain, 
fatigue and endocrine symptoms. 
Limitations: 41% recruitment rate, 
demographically homogenous sample, 
selection biases and adherence differences 
across groups. 
Kirshbaum 
(2006): 
29 articles  focusing 
predominantly on BC 
(BC) 
Systematic 
review (A2) 
To critically review the literature on the benefits of 
whole body exercise for various outcomes (including 
fatigue) during and after BC treatment. Searches 
undertaken in Medline, EMBASE, CINAHL, British 
Nursing Index and the Cochrane Library as well as 
hand searches of Medicine and Science in Sports and 
Exercise journal and various cancer journals. 
Included papers published in English from 1985-
2004. 
The evidence supporting the benefit of 
exercise for CRF was particularly strong. 
Additional studies of higher 
methodological quality are warranted.  
Limitations: methodological limitations of 
the studies reviewed. 
Maguire et al. 
(2009):  
N=24; patients 
receiving adjuvant 
Prospective, 
observational 
To develop and test a side effect risk modelling tool 
(ASyMS©-SERAT) to predict chemotherapy induced 
Nausea, vomiting, fatigue and hand foot 
syndrome were predicted with a high level 
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 chemotherapy for BC 
 
study (B2) 
 
symptoms (nausea, vomiting, mucositis, hand foot 
syndrome, diarrhoea, fatigue) and to identify 
additional data to incorporate into the tool.  
Instrument(s): Questionnaire (integration of the 
Common Toxicity Criteria Adverse Events (CTCAE) 
grading system and the Chemotherapy Symptom 
Assessment Scale (C-SAS).  
of accuracy supporting the future 
development and application of ASyMS©-
SERAT for predicting chemotherapy 
induced symptoms. 
Limitations: sample size, possible 
differences in completion of electronic vs 
paper questionnaire and design of tool for 
four rather than standard 6-8 cycles of 
chemotherapy. 
Loprinzi et al. 
(2008): 
 
Review focused on 
premenopausal 
women with BC. 
 
Literature 
review (A2) 
 
To review literature regarding symptom 
management in pre-menopausal women with BC 
(including CRF and CIPN). 
Searches undertaken in MEDLINE, Current Contents, 
PubMed. Also, included were references from 
relevant articles and abstracts and reports from 
meetings.  
Included papers published in English from 1980-
2006. 
 
 
CRF: Exercise has been shown to positively 
impact on CRF. Current recommendations 
include moderate walking, building up to 
30 min/day, three or more times per week. 
Pharmacological and herbal preparations, 
such as modafinil, long-acting 
methylphenidate and Wisconsin ginseng, 
are being studied but not recommended 
for clinical practice currently.  
CIPN: Gabapentin, lamotrigine, and 
nortriptyline have all been tested in 
randomized, placebo-controlled, double-
blinded research studies; however, none 
have demonstrated any clear benefit for 
CIPN. 
Limitations: Non SR.  
Nakaguchi et 
al. (2013):  
 
N= 439; patients with 
different cancers at 
various stages (most 
advanced) including 
breast (36%) and 
colorectal (24.4%) 
cancer and 
lymphomas (4.6%).  
N= 17 Oncology 
Exploratory 
study (B3) 
 
 
To assess the accuracy of oncology nurses’ 
recognition of supportive care needs and symptoms 
of their patients undergoing chemotherapy.  
Instrument(s): Patients self-administered Short-
Form Supportive Care Needs Survey (SCNS-SF34), 
European Organisation for Research and Treatment 
of Cancer Quality of Life-C30 questionnaire (EORTC 
QLQ-C30), and Hospital Anxiety and Depression 
Scale (HADS).  
Although the prevalence of physical 
symptoms not specific to chemotherapy 
(constipation, insomnia, dyspnea, pain) 
were high, they were less likely to be 
recognized by ON than symptoms 
associated with chemotherapy, such as 
fatigue and appetite loss.  Overall, nurses’ 
awareness of their patients’ supportive 
care needs, physical and psychological 
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nurses (ON), based in 
outpatient 
chemotherapy units 
with a mean of 10 
years’ experience as a 
nurse.  
 
ON were blinded to their patients’ questionnaire 
responses and were asked to complete a nurse 
questionnaire assessing the same endpoints.  
 
symptoms were less than optimal in 
routine care. 
Limitations: Potential selection bias, 
different assessment measures for patients 
and nurses may have influenced results. 
Nurse related contextual issues (e.g. 
workload/rapport) may have impacted on 
accuracy but were not investigated. 
O’Shaughnessy 
(2007) 
  
Patients receiving 
adjuvant treatment 
for BC. 
 
 
Literature 
review (A2) 
 
 
To discuss new guidelines for the supportive 
treatment of patients undergoing adjuvant 
treatment for BC and to evaluate novel strategies 
that can be used to improve the safety of these 
highly effective regimens. 
Review focused on febrile neutropenia 
(FN)/infection and cardiac toxicity. 
 
The NCCN and ASCO guidelines for colony 
stimulating factor (CSF) use now 
recommend routine CSF factor 
administration with cycle one for 
chemotherapy regimens associated with a 
≥ 20% risk of FN or in high risk patients 
even if risk associated with regimen is < 
20%.   
Limitations: Non SR; methodological 
limitations of the studies reviewed. 
Smithies et al., 
(2009): 
 
N=19; patients with 
stages 1 to 111 BC 
commencing adjuvant 
chemotherapy. 
 
 
Exploratory, 
descriptive 
study (B3) 
 
To assess the value of, and perceived need for a 
telephone call to BC patients on the weekend 
following the initiation of chemotherapy.  
Instruments: Telephone questionnaire 
(incorporating a comprehensive list of possible side 
effects). Demographic and oncology physician 
questionnaire to document number and nature of 
calls from patients. 
 
All participants clearly indicated that a 
telephone call shortly after the initiation of 
treatment can be beneficial with regard to 
teaching and/or reminding them about 
whom to contact for help. Conversely, the 
physicians did not see the need for such an 
intervention.  
Limitations: small sample size, limited 
generalizability, sample homogeneity and 
data entry was by same person who 
conducted the telephone intervention.  
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Wu et al. 
(2008):  
 
Patients receiving 
chemotherapy for 
colorectal cancer. 
Four randomized 
studies involving a 
total of 342 patients. 
 
Cochrane 
review (A1) 
 
 
To assess the effect of herbal medicines on 
chemotherapy-related side effects, quality of life 
and objective measures of immune function. 
Searches conducted on Cochrane Library, MEDLINE, 
EMBASE, Chinese Biomedical Base and a hand 
search of Chinese journals ranging from 1966-2003.  
 
Compared with patients treated with 
chemotherapy alone, patients treated with 
chemotherapy and Huangqi decoctions 
were less likely to experience nausea and 
vomiting or low white cell counts and there 
was no evidence of harm from their use.  
Limitations: available studies were limited 
in number, small in size and of low quality. 
Authors noted that chemotherapy 
regimens used in the studies were not 
typical of those used worldwide.  
 
*Typology of the level of evidence (adapted from UK Department of Health) 
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Appendix 3: Description of grey literature  
Table 3 Participating clinical sites: symptom management protocols  
Clinical site Fatigue Nausea Vomiting Oral 
Mucositis 
CIPN Diarrhoea Constipation Febrile 
neutropenia 
/Infection 
PPE Pain Response from 
co-investigator/ 
Clinical site 
Clinical site: a             
Clinical site: b        Self-care  
advice only 
provided 
    
Clinical site: c 
 
           
Clinical site: d 
 
      Self-care  
advice only 
provided 
    
Clinical site: e 
 
           
Clinical site: f 
 
 Self-care 
advice only 
provided 
Self-care 
advice only 
provided 
Self-care 
advice only 
provided 
 Self-care 
advice only 
provided 
Self-care  
advice only 
provided 
    
Clinical sites: 
 g and h 
          Protocols are 
based on 
international 
guidelines 
Clinical sites:  
i-m 
          Protocols are 
based on 
international 
guidelines (not 
available in 
English) 
Symptom management protocol was provided by this clinical site 
Note: it is likely that some of the symptom protocols did not list all of the medications that may have been used subsequently, in particular where guidelines 
were developed for the purpose of telephone triage. 
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Table 4 Fatigue (grey literature) 
Fatigue (symptom management and self-care advice)  
International Cancer Organisations clinical practice guidelines/evidenced based resources 
(2: American Society for Clinical Oncology (ASCO); 3: National Comprehensive Cancer Network (NCCN); 5: Oncology Nursing Society (ONS); 
 6: United Kingdom Oncology Nursing Society (UK ONS)) 
And local clinical site protocols (grey literature) 
(Clinical sites: a, b, c, d, e, f)    
Assessment Screen every patient at initial visit and at regular intervals (inpatients daily, outpatients at follow up visits (2, 3)  
Assessment should be systematic using quantitative/semi quantitative measures (2, 3) and patient self-reports (2, 3, 5, a) 
Focused history identifying disease status, treatment (2, 3, 6, a), medications (2, 3, 6) including non-prescribed/supplements (3, 
5), social support (3) Review of systems (3, a) 
In-depth fatigue history (2, 3, 6) to identify onset, patterns, related factors and impact (3, 6, a) 
Assess treatable contributing factors (e.g. anaemia, emotional distress, pain, sleep problems, nutritional deficits, comorbidities, 
(2, 3, 5, 6, a)  
Grade* Grade 1 Grade 2 Grade 3 Grade 4 
 Fatigue relieved by 
rest 
Fatigue not relieved by rest; limiting 
instrumental activities of daily living (ADLs) 
Fatigue not relieved by rest, limiting self-
care ADL 
----------------- 
    
Symptom 
Management 
Patient and family education and counselling regarding known patterns of fatigue associated with treatment (2, 3, 5, a) 
Manage associated symptoms and treatable contributing factors (2, 3, 5, 6, a) 
Medication as appropriate for pain, emotional distress, nutritional deficits, sleep disorder (3, 5) 
Exercise (aerobic and resistance) (2, 3, 5, a, d, e), self-monitoring of fatigue (3, a), energy conservation measures including rest 
(3, 5, 6, a) 
Distraction techniques (3, 5, a), finding meaning in current situation (3), consider referral to rehabilitation specialists (3,  b, e) 
Physically based therapies (massage) (3, 5), relaxation (3, 5), yoga (2) 
Cognitive behavioural therapy (CBT)/behavioural therapy (2, 3, 5) 
Psychoeducational therapies/educational therapies (2, 3, 5), supportive expressive therapies (3) 
Nutrition advice/nutritional consultation (2, 5, 6, a),  consider psychostimulants after ruling out other causes of fatigue (2, 3, 5) 
*Grades based on the Common Terminology Criteria for Adverse Events (NCI CTCAE V4.0).  
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Table 5 Chemotherapy induced nausea and vomiting (grey literature) 
Chemotherapy induced nausea and vomiting (CINV) (symptom management and self-care advice) 
International Cancer Organisations clinical practice guidelines/evidenced based resources 
(1: European Society for Medical Oncology (ESMO); 2: American Society for Clinical Oncology (ASCO); 3: National Comprehensive Cancer 
Network (NCCN); 4: Multinational Association for Supportive Care in Cancer (MASCC); 5: Oncology Nursing Society (ONS);  
6: United Kingdom Oncology Nursing Society (UK ONS)) 
And local clinical site protocols (grey literature) 
(Clinical sites: a, b, c, d, e, f)    
Assessment Assessment should be ongoing throughout treatment (2, 3) 
Nausea and/or vomiting history (6, a, c) and  associated symptoms (6, a )  
Cancer diagnosis (6, c), treatment to date (6, a), Medication history (6, a, c) including antiemetics taken ( a, c) 
Assess presence of risk factors for CINV (1, 2, 3, 4, 5, a, b, c, d, e) 
Identify other potential causes (3, 5, 6, b, d, e) 
Assess for signs of dehydration ( 6, a, b, d, e) and establish dietary history (fluid/solid food intake) ( 6, a, b, c, d, e) 
Determine grade of nausea and/or vomiting (6, a, b, c, d, e) 
Grade* Grade 1 Grade 2 Grade 3 Grade 4 
Nausea Loss of appetite without 
alteration in eating habits 
Oral intake decreased without significant 
weight loss, dehydration or malnutrition 
Inadequate oral caloric or 
fluid intake; tube feeding, 
TPN, or hospitalization 
indicated 
 
--------------------- 
Vomiting 1 - 2 episodes (separated by 5 
minutes) in 24 hrs 
3 - 5 episodes (separated by 5 minutes) in 
24 hrs 
≥6 episodes (separated by 
5 minutes) in 24 hrs; tube 
feeding, TPN or 
hospitalization indicated 
Life-threatening 
consequences; 
urgent intervention 
indicated 
   ↓↓↓ 
Symptom 
Management 
Review prescribed antiemetic regimen (5, 6, a, b, d, e, f)  
Advise to: take small frequent sips of fluids (6, a, b, d, f), eat small frequent 
amounts of foods (5, 6, a, b, d, f),  avoid spicy, fatty foods (5, b, d, f ), avoid 
strong odours (5, b, d, f), try ginger biscuits/foods/fluids (6, a, b, d, f ), take 
antiemetics prior to meals (5, a) and monitor for signs of dehydration ( 6, a)  
Consider non-pharmacological therapies such as acupuncture/acupressure  
(5, b, d, f), music therapy (5, a), relaxation/progressive muscle relaxation (1, 
4, 5, a, b, f),  behavioural therapy with systematic desensitisation for 
anticipatory CINV (1, 2, 4) 
Present to hospital for immediate review (6, a, b, 
d, e) 
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Contact hospital if symptom(s) persists/worsens ( 6, a, b) 
Phone/review within 12-24 hours (6) 
 Prevention of nausea and vomiting is the goal (1, 2, 3, 4, 5, b, c, d, e) 
Patients receiving highly emetic chemotherapy regimens should receive the three-drug combination of a neurokinin 1 (NK1) 
antagonist, 5-hydroxytryptamine-3 (5-HT3) receptor antagonist and dexamethasone with/without benzodiazepine (1, 2, 3, 4, 5, 
b, c), H2 blocker or proton pump inhibitor (3) or an olanzapine regimen with/without benzodiazepine (3), H2 blocker or proton 
pump inhibitor (3) 
Patients receiving moderately emetic chemotherapy regimens should receive a 5-HT3 receptor antagonist and dexamethasone 
(1, 2, 3, 4, 5, c) with a neurokinin 1 (NK1) antagonist (1, 4, 5) or with/without a neurokinin 1 (NK1) antagonist (2, 3), 
benzodiazepine (2, 3, 5), H2 blocker or proton pump inhibitor (3) or an olanzapine regimen with/without benzodiazepine, H2 
blocker or proton pump inhibitor (3) 
Patients receiving low emetic chemotherapy regimens should receive a single antiemetic agent, either dexamethasone (1, 2, 3, 
4, 5) or a 5-HT3 receptor antagonist (1 ,3, 4) or metoclopramide or prochlorperazine (1, 3, 4, 5, b) with/without benzodiazepine, 
H2 blocker or proton pump inhibitor (3, c) 
Patients receiving chemotherapy regimens of minimal emetic risk should receive no routine prophylaxis (1, 2, 3, 4, c). 
Period of expected nausea and vomiting should be covered with appropriate antiemetics to address anticipatory, acute, and 
delayed CINV (1, 2, 3, 4, 5, c) 
Cannabis/cannabinoids (5), olanzapine for breakthrough CINV (5), progestins (5) 
Managing patient expectations 
*Grades based on the Common Terminology Criteria for Adverse Events (NCI CTCAE V4.0).  
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Table 6 Oral Mucositis (grey literature) 
Oral Mucositis (OM) (symptom management and self-care advice) 
International Cancer Organisations clinical practice guidelines/evidenced based resources 
(1: European Society for Medical Oncology (ESMO); 4: Multinational Association for Supportive Care in Cancer (MASCC); 5: Oncology Nursing 
Society (ONS); 6: United Kingdom Oncology Nursing Society (UK ONS); 8: International Society of Oral Oncology (ISOO) 
And local clinical site protocols (grey literature) 
(Clinical sites: a, b, c, d, e, f)    
Assessment Assess for oral mucositis using a valid and reliable instrument  (5)/recognised (NCI CTAE/WHO) grading scale (1, 6, a, b, d, e) 
Mucositis history: severity of OM (presence/extent of ulceration/candida) (1, 6, a, b, c, d, e),  signs of secondary infection (6, a, 
b, d, e), dehydration (6, a, b, d, e), presence of fever (6, a, b, d, e), pain (1, 5, 6, a, b, d, e), Assessment of fluid/solid food intake 
(1, 6, a, b, d, e) 
Identification of treatment to date (1, 6, a, b, d, e), medication history including use of mouthwashes/analgesia (6, a) 
Careful oral examination of mucous membranes assessment for erythema, ulceration, signs of secondary infection, dehydration 
(6, b, d, e). Swabs if suspicion of bacterial, fungal, viral infections (6, b, d, e)   
Grade* Grade 1 Grade 2 Grade 3 Grade 4 
 Asymptomatic or mild 
symptoms; intervention 
not indicated 
Moderate pain; not 
interfering with oral intake; 
modified diet indicated 
Severe pain; interfering with oral 
intake 
Life-threatening 
consequences; urgent 
intervention indicated 
    
Symptom 
Management 
Use oral care protocols/ensure good oral hygiene (1, 5, 
6, a, b, c, d, e, f), use soft toothbrush (1, 5, a, b, c, f),  
Saline/sodium bicarbonate mouthwash 4-6 times/day (1, 
5, b, c, f), avoid alcohol based mouthwashes (1, 5, a, b, c, 
d, e, f), remove dentures if irritating ( b, d, e ), 
Arrange for antifungal prescription (6, a) if required 
Benzydamine ( b, c, d, e) or sucralfate (a, b, c, d, e) or 
lidocaine based (a, c) mouthwash if required  
Present to hospital for review/admission (6, a). As for grade 1, also: 
Intravenous/parenteral hydration if required (6, b, d, e) 
Antifungal treatment as required (6, b, d), topical acyclovir for 
lips/oral acyclovir (6, b, d, e)/antiviral treatment (1) for coexisting 
viral infection. Benzydamine (5, 6, b, c, d, e) or sucralfate (6, b, c, d, 
e) or doxepin (1, 8) mouthwash as required for pain. Systemic 
opioids (1, 6, 8, b, c, d, e,) as required.  Petroleum jelly, yellow/white 
soft paraffin or normal lip salve to moisten lips (b, c, d, e). 
Consult dietician (6, b, d, e) if inadequate oral intake. 
Prevention Use oral care protocols/ensure good oral hygiene (1, 4, 5, 6, 8, a, b, c, d, e, f) 
Oral cryotherapy in patients receiving bolus 5-fluorouracil chemotherapy (1, 4, 5, 8), prophylactic chlorhexidine mouth rinses (5) 
*Grades based on the Common Terminology Criteria for Adverse Events (NCI CTCAE V4.0).  
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Table 7 Chemotherapy induced peripheral neuropathy (grey literature) 
CIPN (symptom management and self-care advice)  
International Cancer Organisations clinical practice guidelines/evidenced based resources 
(2: American Society for Clinical Oncology (ASCO); 5: Oncology Nursing Society (ONS); 7: European Oncology Nursing Society (EONS)) 
And local clinical site protocols (grey literature) 
(Clinical sites: a, b, c, d, e, f) 
Assessment Comprehensive baseline assessment identifying co-morbidities (2, 7, a) with neurological impact placing patients at higher risk 
(2,7) 
Treatment to date (7, a), identifying other neurotoxic treatments received (7) 
Determine grade of symptom (2, 7, a) 
Identify all medications taken (7, a) (including non-prescribed), supplements (7) 
Neurological assessment (7); assess falls risk (7) 
Grade* Grade 1 Grade 2 Grade 3 Grade 4 
 Asymptomatic; clinical or 
diagnostic observations only; loss 
of deep tendon reflexes or 
paraesthesia 
Moderate symptoms; 
limiting instrumental ADL 
Severe symptoms; limiting self-
care ADL; assistive device 
indicated 
Life-threatening 
consequences; urgent 
intervention indicated 
    
Symptom 
Management 
Duloxetine (2, 5) 
Tricyclic antidepressants (e.g., nortriptyline or desipramine) (2, 5); gabapentin (2, 5) and a topical gel treatment containing 
baclofen (10 mg), amitriptyline HCL (40 mg), and ketamine (20 mg) (2). (It is reasonable to consider all three agents in the 
context of limited treatment options for CIPN and having discussed with patients the potential harms, benefits and costs (2).   
Consider dose reduction or stopping treatment (7) 
Education and support to preserve patient safety (7) Consider referral to rehabilitation specialist (7) 
Assist patients to identify solutions to deal with changes/problems with ADLs/household duties and changes/problems at work 
(7) 
Educate on principles of foot care and approaches to reduce risk of ischaemic or thermal injury in extremities; avoid exposure to 
cold (7). Educate on strategies to prevent symptoms of autonomic dysfunction (e.g. dangling legs prior to standing / adequate 
fluid intake) (7). Advise regarding reporting symptom; reassure that CIPN is an expected side effect of treatment (a, b) 
Grade 4: Present to hospital for immediate review (a) 
 *Grades based on the Common Terminology Criteria for Adverse Events (NCI CTCAE V4.0). 
 
 
 
 40 
 
Table 8 Diarrhoea (grey literature) 
Diarrhoea (symptom management and self-care advice) 
International Cancer Organisations clinical practice guidelines/evidenced based resources 
(5: Oncology Nursing Society (ONS); 6: United Kingdom Oncology Nursing Society (UK ONS)) 
And local clinical site protocols (grey literature) 
(Clinical sites: a, b, c, d, e, f)    
 
Assessment 
Diarrhoea history (duration, severity, characteristics, presence of fever, dizziness, abdominal pain /cramping, weakness (5, 6, a, 
b, c, d, e, f), baseline bowel habits (5, 6). Determine grade of symptom (5, 6, a, b, d, e) 
Treatment to date (6, a, b, c, d, e ), Medication history (6, a, b, c, d, e) 
Dietary history (fluid/solid food intake) (5, 6, a, b, c, d, e) 
Full blood count ( 6, b, c, d, e ), urea and electrolytes (U&E) ( 6, b, c, d, e ), C-reactive protein ( 6), stool sample (6, b, c, d, e) 
Grade* Grade 1 Grade 2 Grade 3 Grade 4 
 Increase of <4 stools per day 
over baseline; mild increase 
in ostomy output compared 
to baseline 
Increase of 4-6 stools per day over 
baseline; moderate increase in 
ostomy output compared to 
baseline;  
Increase >7 stools per day over 
baseline; incontinence; IV fluids >24 
hours; hospitalization; severe increase 
in ostomy output compared to 
baseline; interfering with ADL 
Life 
threatening 
consequences  
(e.g. 
haemodynamic 
collapse) 
    
Symptom 
Management 
Review discharge advice, i.e. take loperamide (5, 6, a, b, c, d, e) or 
codeine phosphate (6, a, c, d, e) as prescribed. 
Take small frequent meals (b, c, d, e), limit intake of certain 
food/fluid e.g. caffeine (6, b, d, e), fruit juice (b, e), alcohol (6, b, d, 
e). Avoid spicy foods (b, d, e), high fibre foods (6, d, e) 
If drinking less than 2-3 litres/day, advise to increase fluid intake (6, 
a, b, c, d, f) and arrange review within 12-24 hours (6, a, b, c, d, e, f) 
Contact hospital with a view to admission if diarrhoea persists 
despite treatment (loperamide as prescribed) and/or new symptoms 
such as fever, nausea and vomiting (6, a, b, c, d, e, f) 
Stop drugs that may be contributing and consider admission based 
on further assessment (6, a, b, c, d). Perianal skin care (6) 
As for grade 1-2 (6, a, b, d, e) 
Present to hospital for immediate review (6, a, b, c, d, e, 
f) and management including octreotide (5, 6, c, d, e) 
IV antibiotics as appropriate (6, b, c) 
Codeine phosphate (b), budesonide (b, c, d, e) 
 
 
 
 *Grades based on the Common Terminology Criteria for Adverse Events (NCI CTCAE V4.0).  
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Table 9 Constipation (grey literature) 
  Constipation (symptom management and self-care advice)  
International Cancer Organisations clinical practice guidelines/evidenced based resources 
(5: Oncology Nursing Society (ONS); 6: United Kingdom Oncology Nursing Society (UK ONS)) 
And local clinical site protocols (grey literature) 
(Clinical sites: a, b, c, d, e, f) 
Assessment Thorough assessment, including normal bowel pattern, medication history (5, 6, a) including use of laxatives (5, a), cancer 
diagnosis and treatment (a) Physical examination (5) 
Determine grade of symptom (6, a) 
Grade* Grade 1 Grade 2 Grade 3 Grade 4 
 Occasional or 
intermittent 
symptoms; occasional 
use of stool softeners, 
laxatives, dietary 
modification, or 
enema 
Persistent 
symptoms with 
regular use of 
laxatives or 
enemas; limiting 
instrumental ADL 
Obstipation with manual evacuation indicated; limiting 
self-care ADL 
Life-threatening 
consequences; urgent 
intervention indicated 
    
Symptom 
Management 
High fibre diet (5, a, b, d, f) 
Increase fluid intake (5, 6, a, b, d, f) (eight 
8 ounce glasses of fluid /day) (5) 
Exercise (5, a, b, d, f) 
Laxatives (5, 6, a) 
 
As for Grades 1 and 2 (5, 6, a, b, d, f). Also:  
Review prescribed stool softeners and laxatives, also 
other (aggravating) medications (6, a)  
Stimulant and/or osmotic laxatives (5) 
Consider admission if associated with symptoms of 
concern (6, a) 
Present to hospital for 
immediate review (6, a) 
Prophylactic bowel regimen and opioid rotation for opioid induced constipation (5) 
Polyethylene glycol (PEG) (5) stimulant laxatives, stool softeners (5), Methylnaltrexone (5) 
*Grades based on the Common Terminology Criteria for Adverse Events (NCI CTCAE V4.0).  
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Table 10 Palmar plantar erythrodysesthesia (grey literature) 
Palmar plantar erythrodysesthesia (PPE)/Hand-foot syndrome (symptom management and self-care advice) 
International Cancer Organisations clinical practice guidelines/evidenced based resources 
(5: Oncology Nursing Society (ONS); 6: United Kingdom Oncology Nursing Society (UK ONS) 
And local clinical site protocols (grey literature) 
(Clinical sites: a, b, c, d, e, f)    
Assessment Identify treatment  taken (type and most recent treatment) (6) 
Ask about presence of other symptoms (6) 
Determine if PPE experienced on previous cycles (6) 
Full blood count, urea and electrolytes (6) 
Vital signs (6) 
Determine grade of symptom (6) 
Grade* Grade 1 Grade 2 Grade 3 Grade 4 
 Minimal skin changes or 
dermatitis (e.g., erythema, 
edema, or hyperkeratosis) 
without pain 
 
Skin changes (e.g., 
peeling, blisters, 
bleeding, oedema) or 
pain, not interfering 
with function 
Severe skin changes (e.g., 
peeling, blisters, bleeding, 
edema, or hyperkeratosis) 
with pain; limiting self-care 
ADL 
----------------- 
 
   
Symptom 
Management 
Reassurance (6), emphasise 
importance of skin care 
regime/regular moisturiser (6, c), 
advise to contact if symptom 
worsens (6), consider pyridoxine as 
per local policy (6, c) for patients 
on capecitabine, 5FU or liposomal 
doxorubicin 
Discuss withholding treatment with 
medical team until resolved to 
grade 0-1 (6), emphasise 
importance of skin care regime (6, 
c), consider pyridoxine as per local 
policy (6, c) 
Inform medical team and stop medication until 
resolved to grade 0-1 (6) (5) review analgesia and 
consider paracetamol if indicated (6), emphasise 
importance of skin care regime (6, c), consider 
pyridoxine as per local policy (6, c) 
 
*Grades based on the Common Terminology Criteria for Adverse Events (NCI CTCAE V4.0).  
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Table 11 Febrile neutropenia (grey literature) 
Febrile neutropenia (FN)/suspected neutropenic sepsis/Infection (symptom management and self-care advice) 
International Cancer Organisations clinical practice guidelines/evidenced based resources 
(1: European Society for Medical Oncology (ESMO); 2: American Society for Clinical Oncology (ASCO); 3: National Comprehensive Cancer 
Network (NCCN); 5: Oncology Nursing Society (ONS); 6: United Kingdom Oncology Nursing Society (UK ONS) 
And local clinical site protocols (grey literature) 
(Clinical sites: a, b, c, d, e, f)    
Assessment Identify actual temperature reading and associated symptoms such as chills/rigors/other signs of infection (6, a, b, d, e, f ) 
Vital signs (1, 2, 6, b, d, f ), oxygen saturation (3, 6, b, f) 
Medications (1, 3, f ) 
Treatment to date (1, 3, 6, a, b, d, f), Comorbidities (1, 2, 3, 6, b, d, e, f  ),  
Identification of past positive microbiology (1, 3, b, d, e f)  
Urgent full blood count with differential (1, 2, 3, 6, b, d, e, f ), other blood tests including tests of  renal and liver function ( 1, 3,  
6, b, d, e, f ), coagulation screen (1, 6, b ), C-reactive protein ( 1, 6, b, d, e, f ), blood cultures  (peripheral and from central lines if 
present) ( 1, 2, 3, 6, b ,d, f,) 
Review of systems to identify signs and/or symptoms of infection (1, 2,  3,  6, a, b, d, e,  f) 
Physical examination to identify signs and/or symptoms of infection (1, 2, 3, 6, b, d, e, f) 
Sputum, urine, stool specimens and skin swabs where clinically indicated (1, 2, 3, 6, b, f) 
Chest radiograph (1 ) if clinically indicated (3, 6, b, d, e, f) 
Grade* Grade 1 Grade 2 Grade 3 Grade 4 
  
__________________ 
 
 
 
___________________ 
Absolute neutrophil count (ANC) <1000/mm3 
with a single temperature of >38.3 degrees C 
(101 degrees F) or a sustained temperature 
of≥38 degrees C (100.4 degrees F) for > one hour 
Life-threatening 
consequences; urgent 
intervention indicated 
  
  
Symptom 
Management 
Calculate MASCC score (1, 2, 3, b, d, e, f) 
Initiate Early Warning Score Chart (6, b, f) 
Close monitoring for sepsis (2, 6, b, d, e, f) 
Intravenous fluids if required (1, 6, b, d ) 
Low risk patients: administer inpatient (1, f ) or outpatient/home based (2, 3, b, d, e ), oral antibiotic therapy for some patients 
High risk patients: administer inpatient broad spectrum intravenous antibacterial therapy (1, 2, 3, b, d, f) 
Administer colony stimulating growth factor (G-CSF) where ≥20% risk of FN (1, 2, 3, 5) 
Anti-fungal treatment if required (1, 3, b, d) 
Anti-viral treatment if required (1, 3) 
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Infection 
prevention 
strategies 
Adherence to general infection control recommendations (3, 5), catheter care bundle for prevention of central line associated 
infection (5) 
Antibiotic prophylaxis in at risk patients (3, 5), antifungal prophylaxis in at risk patients (1, 3, 5), Antiviral prophylaxis for select at 
risk patients (3, 5) 
Colony stimulating factors for at risk patients (1, 2, 3, 5) 
Hand washing/hand hygiene with alcohol sanitizer (3, 5) 
Influenza vaccination (3, 5), pneumococcal and meningococcal vaccination (3, 5) 
Antibiotic abdominal lavage in CRC surgery (5), antimicrobial coated CVC catheters in adults (5), preoperative antibiotics 
Chlorhexidine impregnated washcloths, chlorhexidine bath (5) 
Environmental interventions (5), pre-construction planning (5) 
 
*Grades based on the Common Terminology Criteria for Adverse Events (NCI CTCAE V4.0).  
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Table 12 Pain (grey literature) 
Pain (symptom management and self-care advice) 
International Cancer Organisations clinical practice guidelines/evidenced based resources 
(1: European Society for Medical Oncology (ESMO); 2: American Society for Clinical Oncology (ASCO); 3: National Comprehensive Cancer 
Network (NCCN); 4: Multinational Association for Supportive Care in Cancer (MASCC); 5: Oncology Nursing Society (ONS); 6: United Kingdom 
Oncology Nursing Society (UK ONS); 7: European Oncology Nursing Society (EONS)) 
And local clinical site protocols (grey literature) 
(Clinical sites: a, b, c, d, e, f)    
Assessment Initial and ongoing assessment of pain and of patients with pain at any stage (1, 3) 
Cancer diagnosis (3, 7, a ), cancer treatment (3, 7, a), pain onset (1, 3, 7, a), location/radiation (1, 3, 7, a ), duration (1, 3, 7, a), 
type (1, 3), character (1, 3, 7, a, ), severity (using standardised assessment scale) (1, 3, 7, a ), current analgesia (1, 3, a, 7), 
associated symptoms/aggravating and relieving factors (1, 3, 7, a ), comorbidities (1, 3), interference with ADLs (1, 3) 
Psychosocial assessment (1, 3, 7) 
Physical examination (1, 3, 7), functional assessment (1, 3) 
Radiological and/or biochemical investigations (1, 3) 
Grade* Grade 1 Grade 2 Grade 3 
 Mild pain Mild to moderate pain Moderate to severe pain 
 
   
Symptom 
Management 
Nonsteroidal anti-
inflammatory (NSAID) drug (1, 
3, 5) and/or 
Acetaminophen/paracetamol 
(1, 5), consider short acting 
opioid (3), consider 
adding/adjusting adjuvant 
analgesics (3) 
Weak opioid such as codeine, tramadol 
and dihydrocodeine in combination with 
non-opioid analgesics (1, 3) 
Consider: pain specialty consultation 
(3), adding/adjusting adjuvant 
analgesics (3) 
specific pain syndrome problems (3) 
Present to hospital for immediate review (a),  
Opioids (1, 5,), oral morphine (first choice) or 
parenterally (1, 3) 
Consider: pain specialty consultation (3), 
adding/adjusting adjuvant analgesics (3) 
specific pain syndrome problems (3) 
 Analgesia for chronic pain should be prescribed on a regular basis rather than on an ‘as required’ schedule (1, 3) 
Administer via oral route as a first choice (1, 3, 5) 
Rescue doses of medications in addition to ‘around the clock’ scheduled doses should be prescribed for breakthrough pain (BTP) 
episodes (1, 3) 
Neuropathic pain should be treated with opioids +/- non-opioids +/- co-analgesics (1, 3, 5) 
Opioid rotation using an equianalgesic chart if opioid regimen ineffective or if side effects intolerable (1, 3) 
Laxatives for prophylaxis and management of opioid-induced constipation (1, 3, 5)  
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Anti-emetics for opioid-related nausea and vomiting (1, 3, 5) 
 Consider integrative interventions/non pharmacological interventions in conjunction with pharmacological interventions (b, 5, 
3, 7) 
Psychosocial support (1, 3, 7) and patient and family caregiver education (1, 3, 7) 
*Grades based on World Health Organisation (WHO) grading system 
 
 
 
 
 
